

Cite this: *Food Funct.*, 2023, **14**, 1648

# Raw milk kefir: microbiota, bioactive peptides, and immune modulation†

Ton Baars,<sup>\*‡<sup>a</sup></sup> Betty van Esch,<sup>‡<sup>a</sup></sup> Luuk van Ooijen,<sup>a,b</sup> Zuomin Zhang,<sup>c</sup> Pieter Dekker,<sup>‡<sup>c,d</sup></sup> Sjef Boeren,<sup>d</sup> Mara Diks,<sup>a</sup> Johan Garssen,<sup>‡<sup>a</sup></sup> Kasper Hettinga,<sup>‡<sup>c</sup></sup> and Remco Kort<sup>‡<sup>\*b,e</sup></sup>

This study aims to characterize the microbiota and peptidomic composition of raw milk kefir, and to address the potential anti-allergic effects of raw milk kefir using validated research models for food allergy. Raw milk kefir was produced after incubation with a defined freeze-dried starter culture. Kefir was sampled during fermentation at seven time intervals. For comparison, kefir was also prepared from heat-treated milk. Peptide compositions were determined for the raw and heated milk, and kefir end products made from these milks. In a murine food allergy model, the two kefir end products were investigated for their allergy modulating effects. In both kefirs, we identified amplicon sequence variants identical to those in the starter culture, matching the bacteria *Lactococcus lactis*, *Streptococcus thermophilus*, *Leuconostoc* and the yeast *Debaryomyces*. In raw milk kefir, additional sequence variants of *Lactococcus lactis* and the yeasts *Pichia* and *Galactomyces* could be identified, which were absent in heated milk kefir. Analysis of peptide compositions in both kefirs indicated that the number and intensity of peptides drastically increased after fermentation. Heating of the milk negatively affected the diversity of the peptide composition in kefir. Only raw milk kefir suppressed the acute allergic skin response to the food allergen ovalbumin in sensitised mice. These effects coincided with differences in the T-cell compartment, with lower percentages of activated Th1 cells and IFN $\gamma$  production after treatment with kefir made from heated milk. The results of this study indicate specific properties of raw milk kefir that may contribute to its additional health benefits.

Received 26th October 2022,  
Accepted 11th January 2023

DOI: 10.1039/d2fo03248a

rsc.li/food-function

## 1. Introduction

Fermentation is the oldest way of milk conservation, transforming milk into kefir and yoghurt, as well as fresh or ripened cheese. Defined starter cultures (SC) based on selected microorganisms were not used until the early 1900s, implicating that fermentation was initiated by microorganisms originating from the environment and equipment.<sup>1</sup> Over the last few decades, there has been increasing interest in kefir, a drinkable milk product that originates from Eastern Europe, Turkey, or the Caucasus region. In contrast to yoghurt fermentation, which is based on thermophilic bacteria, kefir is fermented by mesophilic bacteria as well as yeasts. Wild starters of kefir are based on kefir grains or SCOBY, a symbiotic community of bacteria and yeast containing a matrix of the exopolysaccharide kefiran and proteins. The microbial species in these kefir grains include lactic acid bacteria, acetic acid bacteria and yeasts. The most common method to produce kefir on an industrial scale is based on fermentation with defined, often freeze-dried SCs.<sup>2</sup> These SCs are based on a selection of microbial species, including the bacteria *Streptococcus*, *Lactobacillus*, and *Lactococcus* as well as yeasts *Kluyveromyces* and *Debaryomyces*.<sup>3</sup> These bacteria and yeasts multiply during

<sup>a</sup>Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. E-mail: a.baars@uu.nl

<sup>b</sup>Amsterdam Institute for Life and Environment, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. E-mail: r.kort@vu.nl

<sup>c</sup>Food Quality and Design Group, Wageningen University & Research, Wageningen, The Netherlands

<sup>d</sup>Laboratory of Biochemistry, Wageningen University & Research, Wageningen, The Netherlands

<sup>e</sup>ARTIS-Micropia, Amsterdam, The Netherlands

† Electronic supplementary information (ESI) available: Supplementary file 1: Overview of the sample cycle threshold values, amplicon sequence variants, and metadata. Supplementary file 2: Relative abundance of microbial species in raw milk and heated milk. Dynamics of the microbial population after the first day of fermentation at 28 °C and during three weeks of storage at 4 °C. Supplementary file 3: Precursor proteins of kefir peptides with the total peptide intensity (log 10) in raw milk (RM), heated milk (HM), raw milk kefir (RMK), and heated milk kefir (HMK). Supplementary file 4: Overview of bioactivities found in the Milk Bioactive Peptide Database (MBPDB),<sup>35</sup> which match with identified peptide sequences. Supplementary file 5: Relative intensities of amino acids in the P1 and P1' position for all peptides identified in (A) heated milk kefir (HMK) and (B) raw milk kefir (RMK). Relative intensities of amino acids in the P1 and P1' position for uniquely identified peptides in (C) HMK and (D) RMK. See DOI: <https://doi.org/10.1039/d2fo03248a>

‡ Shared first authors.



the anaerobic fermentation process. According to the Codex Alimentarius (2003), kefir should contain at least  $10^7$  cfu mL<sup>-1</sup> bacteria, and at least  $10^4$  cfu mL<sup>-1</sup> yeast.

Fermented dairy belongs to the group of 'functional foods' or 'nutraceuticals'.<sup>4</sup> The health impact of fermented food consumption is widely accepted, and benefits may be based on multiple mechanisms.<sup>5</sup> For kefir, lactose fermenting microorganisms are responsible for the transformation of lactose into lactate and other organic acids, causing a drop in pH. During fermentation, peptides are produced because of proteolytic degradation of predominantly caseins,<sup>6</sup> along with the generation of short chain fatty acids, ethanol, and vitamins.<sup>4</sup> Some kefir peptides show biological activity, including angiotensin-converting enzyme (ACE)-inhibitory, antimicrobial, immunomodulating, opioid, mineral binding, antioxidant, and antithrombotic effects.<sup>6,7</sup> The impact of kefir on gastrointestinal health is partly based on the changes in the gut microbiome, and the improvement of gut dysbiosis and gut barrier.<sup>4</sup> Altered gut colonization and gut dysbiosis are associated with increased risk of immune related diseases, like asthma and allergies.<sup>8</sup> Overall health claims associated with kefir consumption were reviewed from different perspectives,<sup>9-13</sup> but studies on the impact on food allergic diseases are limited. In healthy volunteers, two weeks of kefir consumption changed the level of several cytokines, indicating an increase of the Th1 immune response and a decrease of the Th2 immune response.<sup>14</sup> In a study utilizing an ovalbumin sensitisation murine asthma model, it was found that mice receiving intra-gastric kefir had lower levels of airway hyper-responsiveness (AHR) than control mice, and, impressively, had lower levels of AHR than the positive control group receiving an anti-asthma drug.<sup>15</sup> In young rats, kefir consumption improved the intestinal mucosal and systemic immune responses after the ingestion of cholera toxin.<sup>16</sup> Although pre-clinical studies on kefir affected allergy related molecules like IgE after kefir consumption as well as reduced inflammation and airway hyperresponsiveness in allergic asthma, it is currently unknown whether kefir has the potential to prevent food allergy symptoms.

Kefir is usually made from heat-treated milk, using skimmed milk, or homogenized full fat milk. Knowledge about the impact of kefir made from unheated and non-homogenized full fat milk is missing, and there is an increasing amount of literature on the impact of milk processing on its composition in relation to human health.<sup>17-19</sup> Various epidemiological studies have shown reduced incidences of asthma and allergies in children who consumed raw bovine milk.<sup>20</sup> After the raw milk was heated, the protection was lost, even in farm children.<sup>21</sup> These epidemiologic observations were confirmed in recent studies where we showed anti-allergic effects of raw milk in murine food allergy models and a clinical pilot study with eleven allergic children.<sup>22-24</sup> It could be shown that the protection is related to the whey fraction of the milk, containing a wide range of heat-sensitive proteins.<sup>23</sup>

The aim of this study was to evaluate the impact of kefir either made from raw or heated whole milk. Hereto, raw milk kefir (RMK) and heated milk kefir (HMK) were characterized

by the analysis of the microbiota and peptide compositions. Both RMK and HMK were investigated for their allergy protective effects in a murine food allergy model. Microbiota and peptide composition were used to generate hypotheses about potential mechanisms of allergy protection.

## 2. Materials and methods


### 2.1. Kefir production and sampling

Kefir was produced at a commercial dairy plant, the Raw Milk Company (De Lutte, The Netherlands). The raw milk came from a mix of 80 dairy cows in one morning milking. Raw bulk milk was cooled at the farm to approximately 25 °C. The time between the end of milking and the start of fermentation was less than two hours. The farm was organic certified, according to SKAL/EU regulations. The kefir produced this way is referred to as RMK. RMK was produced by 2%-addition to raw milk of a freeze-dried defined starter EXACT® kefir culture, containing the bacterial species *Leuconostoc* sp., *Streptococcus thermophilus*, *Lactococcus lactis* subsp. *cremoris*, *L. lactis* subsp. *lactis*, *L. lactis* biovar *diacetylactis*, and the yeast *Debaryomyces hansenii* (Chr. Hansen, Hoersholm, Denmark). Fermentation was carried out at 28 °C for 24 hours in tanks of 1000 L. Before bottling, the kefir was gently mixed. Bottles of 1 L were stored at 4 °C.

At seven different time points, samples were taken both during the fermentation process of the raw milk as well as during the storage of the final kefir. To control the fermentation process, the pH was measured every 1 to 3 hours. To evaluate the impact of heating, raw milk was heated to produce HM kefir (HMK). After thermisation, 3 L of milk was brought to 100 °C (microbiota profiling and peptidomics) or heated for 30 min at 72 °C (murine allergy model), followed by immediate cooling to 24 °C. In contrast to RMK, HMK was only sampled at two timepoints: milk after heating before inoculation and at the end of kefir processing after 24 hours. A schematic overview of the fermentation process and the samples collected and analysed is displayed in Fig. 1.

### 2.2. Enumeration of total bacteria, lactic acid bacteria and yeasts

Three different types of nutrient agar plates were used to determine the number of total bacteria, lactic acid bacteria and



**Fig. 1** Timeline of the processing and sample collection steps for kefir production. Green boxes indicate the samples taken for microbial community analysis. Abbreviations: RM = raw milk; HM = heated milk; SC = defined kefir starter culture (Chr. Hansen); RMK = raw milk kefir (final product obtained after 1 day of fermentation); HMK = heated milk kefir (final product obtained after 1 day of fermentation); 1 h, 1 hour; 1 d, 1 day; 1w/3w, 1 or 3 weeks.



yeasts. Petri dishes with culture media and the NaCl solutions (0.9%, pH = 7.0) for the dilution series were provided by Biotrading Benelux BV (Mijdrecht, The Netherlands). Total bacterial counts were determined on Tryptic Soy Agar (TSA), lactic acid bacteria on de Man, Rogosa and Sharpe (MRS) agar, and yeasts on Sabouraud Dextrose Agar (SDA) with chloramphenicol to prevent bacterial growth. For each sample (Fig. 1), serial dilutions were made and colony forming units were determined after 24 to 30 hours of incubation at 30 °C.

### 2.3. Amplicon sequencing of 16S rRNA and ITS

**2.3.1. DNA extraction, mock community, and genomic DNA spike-in.** Samples were taken during milk fermentation and immediately transferred to dry ice in 2 mL tubes to stop further fermentation. At the end of the day all samples were stored at -18 °C. After two weeks the whole set of samples was transported on dry ice to the laboratory and stored at -80 °C before further analysis. The microbiota composition was determined by sequencing of the V3–V4 amplicon from the bacterial 16S rRNA gene and the fungal internal transcribed spacer 1 (ITS). The DNA isolation efficiency, read depth and taxonomic assignment of the amplicons was determined by the use of a mock microbial community (Microbial community standard II log distribution, zymoBIOMICS™, Irvine, CA, United States). A genomics spike-in (Microbial community DNA standard II log distribution, zymoBIOMICS™) was added to the samples as a control. Three replicates of three different HMK samples were determined to evaluate the reproducibility of bacterial microbiota and mycobiota compositions in this study.

A specific milk bacterial DNA isolation kit (Norgen Biotek, Thorold, Canada) was used with slight modifications of the manufacturer's protocol. The following amount of the sample was used: for unfermented milk 1 mL per sample, for fermented samples 0.2 mL with the addition of 0.8 mL phosphate buffer. For the defined SC, 20 mg was added to 1 mL phosphate buffered saline solution. The manufacturer's recommendation of addition of 75 µL mock microbial community suspension was used, equivalent to a total of 220 ng of genomic DNA. All fermented samples were passed through a 21-gauge syringe (Sigma-Aldrich, St Louis, MS, United States) to reduce the viscosity. After centrifuging for 2 min at 20 000g, the supernatant was removed. The cell pellet was resuspended in 100 µL resuspension solution A from the DNA isolation kit and transferred to a 2 mL screw cap tube preloaded with 0.5 g autoclaved glass beads. The samples were chilled on ice for 1 minute, followed by 10 seconds of bead shaking treatment at the speed set to 6 meters per second on a Fastprep®-24 5G Instrument (MP Biomedicals, Solon, OH, United States). Cycles of chilling and shaking were performed eight times. After mechanical cell lysis, the DNA isolation kit manufacturer's protocol was applied as specified for Gram-positive and unknown bacterial species.

**2.3.2. Real-time polymerase chain reaction.** The spike-in DNA derived reads per sample were aimed to be limited to 10% of the total reads per sample. Therefore, a quantitative

SYBR based qPCR on the 16S rRNA gene was deployed on the gDNA from the samples and on the 5 times 10-fold serial diluted spike-in DNA. Per reaction, 1 µL gDNA template and 19 µL mastermix was used per reaction, which consists of 10 µL SYBR mastermix from SensiFast SYBR® Hi-Rox-Kit (Meridian Bioscience, London, United Kingdom) 0.8 µL forward F357 primer: "CCTACGGGAGGCAGCAG" (10 µM), 0.8 µL reverse R518 "ATTACCGCGGCTGCTGG" (10 µM) primer and 5 µL nucleotide-DNase free water. The qPCR was performed on a 7300 RT-PCR system (Applied Biosystems, Waltham, MA, United States) with the amplification setup of an initial start for 10 min at 95 °C followed by 40 amplification cycles with denaturation at 95 °C for 5 s, annealing at 58 °C for 10 s and elongation for 30 s at 73 °C. The spike-in was added to all samples except for the RM and HM. A complete overview of the sample Ct values and estimated and measured concentrations of added spike-in can be found in ESI 1.†

**2.3.3. DNA Quality control, library preparation and sequencing.** DNA quality control, metagenome amplicon amplification, library preparation and sequencing were performed by MacroGen (Seoul, Korea). The double-stranded DNA binding dye, Picogreen (cat. #P7589, Invitrogen, Waltham, MA, United States) was added and DNA was quantified by Victor 3 fluorometry (Waltham, MA, United States). Amplicons of the V3–V4 region of the 16S rRNA gene and the ITS1 region and library prep were generated using the Herculase II Fusion DNA Polymerase Nextera XT Index Kit V2 (Illumina, San Diego, CA, USA). The products of the library prep were validated by an Agilent TapeStation D1000 (Santa Clara, CA, USA). Paired-end sequencing was performed with 2 × 300 base pairs (bp) per sequence on the Illumina MiSeq System platform. The bcl2fastq package from Illumina was used to demultiplex the sequence data and to convert the base calls binary into FASTQ files.

**2.3.4. Data processing.** Demultiplexed and adapter trimmed sequences were visualized and loaded into Qiime2-2020.2<sup>25</sup> through the paired-end manifest method. Based on the quality plots, sequences were truncated at the median nucleotide Phred score of <30. The trimmed sequences (removal of primers) were denoised, paired end joined, followed by the removal of chimeras by the DADA2 plugin.<sup>26</sup> Taxonomic annotation of the amplicons was performed by a Naive Bayes based model, trained on the 16SrRNA V3–V4 region extracted from the SILVA 138 database.<sup>27</sup> For the ITS classification the model was trained on full length sequences from the dynamic clustered UNITE-V8 database.<sup>28</sup> Taxonomic classification was performed on an Amazon Web Services (Seattle, WA, USA), AWS EC2 QIIME 2 Core – version 2020.2.<sup>25</sup> The feature table was exported to a biological observation matrix (.biom) file and converted into a tab separated file which was concatenated with the assigned taxonomy and amplicon sequence variant (ASV). The spike-in ASVs were identified and removed. The ASVs were blasted against the National Centre for Biotechnology Information (NCBI) database and the taxonomic assignment was manually curated. The relative abundance of ASV per sample was calculated by



the ratio of reads ASV/total non-spike-in ASV reads per sample. Visualization of the data was carried out using Graphpad Prism version: 6 (San Diego, CA, USA).

**2.3.5. Data availability.** All raw sequence data generated in this project are available at NCBI under the bio-project number: PRJNA716278.<sup>29</sup> The ASVs and metadata are presented in ESI 1.†

## 2.4. Kefir peptidomics

**2.4.1. Sample preparation.** The  $-80\text{ }^{\circ}\text{C}$  stored samples were thawed and subsequently centrifuged at  $16\ 000g$  and  $4\text{ }^{\circ}\text{C}$  for 10 min to remove caseins and fat.<sup>7</sup> Remaining proteins were precipitated by the addition of an equal volume of  $200\text{ g L}^{-1}$  trichloroacetic acid in Milli-Q water, followed by centrifugation at  $3000g$  and  $4\text{ }^{\circ}\text{C}$  for 10 min. The peptide fraction in the supernatant was cleaned-up with a solid phase extraction (SPE) on C18+ Stage tip columns (prepared in-house).<sup>30</sup> SPE was carried out as described before,<sup>31</sup> using  $100\text{ }\mu\text{L}$  supernatant of each sample. Finally, peptides were reconstituted to  $50\text{ }\mu\text{L}$  with  $1\text{ mL L}^{-1}$  formic acid in water.

**2.4.2. LC-MS/MS analysis.** Peptide samples were analysed by nano LC-MS/MS as described before, with minor adjustments.<sup>32</sup> In brief,  $4\text{ }\mu\text{L}$  peptide solution was loaded onto a  $0.10 \times 250\text{ mm}$  ReproSil-Pur 120 C18-AQ  $1.9\text{ }\mu\text{m}$  beads analytical column (prepared in-house) at  $825\text{ bar}$ . Peptides were separated in acetonitrile in water with the gradient changing from 9 to 34% with 0.1% formic acid over 50 min (Thermo nLC1000). Full scan FTMS spectra were obtained using a Q-Exactive HFX (Thermo Electron, San Jose, CA, USA) in the positive mode between 380 and  $1400\text{ m/z}$  at a resolution of 60 000. The 25 most abundant positively charged peaks (2–5+) in the MS scan were isolated and fragmented (HCD) with an isolation width of  $1.2\text{ m/z}$  and 24% normalized collision energy. MSMS scans were recorded at a resolution of 15 000 in the data-dependent mode with a threshold of  $1.2 \times 10^5$  and 15 s exclusion duration for the selected  $m/z \pm 10\text{ ppm}$ .

**2.4.3. Data processing and analysis.** Raw LC-MS/MS data files resulting from the peptidomics analysis were processed using MaxQuant v1.6.1.0.<sup>33</sup> For an initial search, a database comprising all *Bos Taurus* protein sequences from the UniProtKB<sup>34</sup> was used. For this search, minimum peptide length was set to 8 and maximum peptide length to 25 amino acids.

In a second search, a new database was created comprising only the protein sequences of which peptides were identified in the first, initial search. This new database comprised 39 protein sequences and was used for a new search in which the minimum peptide length was set to 4 and the maximum peptide length to 45 amino acids. The rationale behind this search strategy was to comprehensively map the complete kefir peptidome with short processing times. In both searches, oxidation of methionine, n-terminal acetylation, deamidation of asparagine and glutamine and phosphorylation of serine and threonine were set as variable modifications. Peptides were filtered on identification score ( $>80$ ) and only peptides from proteins with  $>5$  unique peptides were retained. Raw, relative

peptide intensities were used for data analysis and precursor proteins were determined from the MaxQuant proteinGroups result file as described before.<sup>35</sup> Bioactive properties of identified peptide sequences were searched using the Milk Bioactive Peptide Database (MBPDB).<sup>36</sup> The search type used in the database was 'precursor' with a similarity threshold of 100%. Results were filtered on the requirement that the length of the bioactive sequence  $> 4$  amino acids and that the length of the identified sequence  $< 2 \times$  length bioactive sequence.

Sequence logos were created for the P1 and P1' positions of the identified peptides. N- and C-terminals of the peptides were summed, and intensities of the amino acids were plotted using the R package ggseqlogo, version 0.1.<sup>37</sup>


## 2.5. Murine food allergy model

**2.5.1. Animals.** Three-week-old, specific pathogen-free, female C3H/HeOuJ mice (The Jackson Laboratory, Bar Harbor, ME, USA) were housed at the animal facility of Utrecht University (Utrecht, The Netherlands) in filter-topped makrolon cages (one cage/group,  $n = 6\text{--}8$  per cage) with standard chip bedding, Kleenex tissues and a plastic shelter, on a 12 h light/dark cycle with access to food ('Rat and Mouse Breeder and Grower Expanded'; Special Diet Services, Witham, UK) and water *ad libitum*. Upon arrival, mice were randomly assigned to the 4 experimental groups and were habituated to the laboratory conditions for 6 days prior to the start of the study. All animal procedures were approved by the Ethical Committee for Animal Research of the Utrecht University and complied with the European Directive 2010/63/EU on the protection of animals used for scientific purposes (AVD108002015346).

On experimental days 0, 7, 14, 21 and 28, mice ( $n = 8$  per group) were orally sensitised, by using a blunt needle, to the hen's egg protein ovalbumin (OVA) ( $20\text{ mg}/0.5\text{ mL PBS}$ ; grade V; Sigma-Aldrich) using cholera toxin (CT;  $15\text{ }\mu\text{g}/0.5\text{ mL}$ ; List Biological Laboratories, Campbell, CA, United States) as an adjuvant. Sham-sensitised mice (PBS/PBS) received CT alone ( $15\text{ }\mu\text{g}/0.5\text{ mL PBS}$ ). The following experimental groups (treatment/sensitisation and challenge): PBS/PBS, PBS/OVA (allergic control), RMK/OVA and HMK/OVA. HMK was prepared from heated milk with the same starter culture. After 24 hours of fermentation, both RMK and HMK kefir samples were kept at  $-18\text{ }^{\circ}\text{C}$  and thawed on the day of challenge. For the treatment with the different kefir 0.5 ml of PBS, RMK or HMK were given  $3\times/\text{week}$  by oral gavage from day  $-1$  to 32. On day 33, mice were challenged intradermally (i.d.) in both ear pinnae with OVA ( $10\text{ }\mu\text{g}/20\text{ }\mu\text{L PBS}$ ) to evaluate the acute allergic symptoms after i.d. challenge. Allergen-specific IgE in blood and percentages of activated Th1, Th2, Foxp3+ regulatory cells and IFN $\gamma$  production were measured on day 34 and 16 hours after oral OVA challenge ( $50\text{ mg OVA}/0.5\text{ mL PBS}$ ) in MLN or spleen. A schematic overview of the experimental timeline is shown in Fig. 2.

**2.5.2. Evaluation of the acute allergic response.** To assess the severity of the acute allergic symptoms upon intradermal OVA challenge, both ear pinnae were injected with OVA and





**Fig. 2** Schematic overview of the study design. Female C3H/HeOuJ mice were PBS treated or orally sensitised to OVA on days 0, 7, 14, 21, and 28 using CT as the adjuvant. The experimental set-up resulted in 4 groups: Sham-sensitised (PBS/PBS), OVA sensitised control mice (PBS/OVA), OVA sensitised RMK treated mice (RMK/OVA) and OVA sensitised HMK treated mice (HMK/OVA). PBS, RMK or HMK were given 3x/week by oral gavage (i. g.) from day -1 to 32. On day 33 mice were challenged i.d. with OVA to evaluate the allergic reaction. The acute allergic skin response, anaphylactic shock symptoms and body temperature are evaluated at 1 hour. Allergen-specific IgE, cytokine production, percentages of activated Th1 and Th2 cells were assessed on day 34, 16 hours after oral OVA challenge. OVA = ovalbumin; CT = cholera toxin. RMK = raw milk kefir; HMK = Heated milk Kefir; i.d. = intradermal; i.g. = intragastrically by oral gavage.

the acute allergic skin response, anaphylactic shock symptoms and body temperature were measured. The acute allergic skin response, expressed as  $\Delta$  ear swelling ( $\mu\text{m}$ ), was calculated by subtracting the mean basal ear thickness from the mean ear thickness measured 1 h after the intradermal challenge. Ear thickness at both timepoints was measured in duplicate for each ear using a digital micrometer (Mitutoyo, Veenendaal, The Netherlands). To perform the intradermal challenge and both ear measurements, mice were anesthetized using inhalation of isoflurane (Abbott, Breda, The Netherlands). The severity of the anaphylactic shock symptoms was scored 30 min after the intradermal challenge by using a previously described, validated, scoring table.<sup>38</sup>

**2.5.3. Measurement of serum OVA-specific IgE.** Blood collected *via* cheek puncture prior to sacrifice (day 34) was centrifuged at 10 000 rpm for 10 min. Serum was subsequently obtained and stored at  $-20\text{ }^{\circ}\text{C}$  until analysis of OVA-specific IgE and IgG levels by means of ELISA as described elsewhere.<sup>24</sup>

**2.5.4. Th2 and Th1 percentages and *ex vivo* IFN $\gamma$  production.** Single cell splenocyte and mesenteric lymph node (MLN) suspensions were obtained by passing the organs through a  $70\text{ }\mu\text{m}$  filter. After red blood cell lysis, cells were blocked for 20 min in PBS containing 1% BSA and 5% FCS.  $8 \times 10^5$  cells were plated per well and incubated for 30 min at  $4\text{ }^{\circ}\text{C}$  with different antibodies (eBioscience, Breda, The Netherlands or BD, Alphen aan de Rijn, The Netherlands, unless otherwise stated) against CD4, CD25, CD69, CXCR3, T1ST2, and Foxp3 and isotype controls were used. Flow cytometry was performed using a FACS Canto II (BD, Alphen aan den Rijn, The Netherlands) and analysed using FACSDiva software (BD). For cytokine release, splenocytes ( $8 \times 10^5$  per well) were incubated in RPMI1640 supplemented with penicillin ( $100\text{ U mL}^{-1}$ ), streptomycin ( $100\text{ }\mu\text{g mL}^{-1}$ ), and 10% FBS. Cells were stimulated for 5 days with OVA ( $10\text{ }\mu\text{g mL}^{-1}$ ). Supernatants were harvested for cytokine measurements by ELISA according to the manufacturer's recommendations (eBioscience).


**2.5.5. Statistical analysis.** Experimental results are expressed as mean  $\pm$  SEM, as individual data points or as box-and-whisker Tukey plots when data were not normally distributed. Differences between pre-selected groups were statistically determined using one-way ANOVA, followed by Bonferroni's multiple comparisons test for preselected groups. OVA-specific IgE, OVA-specific IgG1 levels and anaphylactic shock scores were analysed using Kruskal-Wallis test for non-parametric data followed by Dunn's multiple comparisons test for pre-selected groups. Statistical analyses were performed using GraphPad Prism software (version 7.03; GraphPad Software, San Diego, CA, USA) and results were considered statistically significant when  $p < 0.05$ .

## 3. Results

### 3.1. Microbial growth and acidification during fermentation and storage

The growth of lactic acid bacteria at  $28\text{ }^{\circ}\text{C}$  and concomitant production of lactic acid showed a typical pattern: a relatively slow reduction of pH during the first hour, followed by a rapid decrease to pH 4.3 at 24 hours. A short lag phase was evident for yeast, but lactic acid bacteria show exponential growth from the first hour of incubation for starter cultures grown on lactose. The storage period from one day to three weeks at  $4\text{ }^{\circ}\text{C}$  was characterized by a further slow decline of the pH (Fig. 3). The total increase in total bacterial load during the 24 hours of fermentation at  $28\text{ }^{\circ}\text{C}$  for RMK was about five orders of magnitude, from approximately  $10^3$  to  $10^8\text{ CFU mL}^{-1}$ . An increase between four and five orders of magnitude in bacterial load can also be derived from the 16S rRNA gene-based cycle threshold values (Ct) of the quantitative PCR, as the Ct values decreased from 24 to 10 in the first 24 hours during the fermentation process. RMK and HMK do not significantly differ in Ct values or CFU counts of total or lactic acid bacteria after 1 day of fermentation. However, HMK showed about 40-fold






**Fig. 3** Acidity, microbial plate counts and cycle threshold values (Ct) during growth and storage of raw milk kefir. The acidity is expressed in pH-values (circles), the total microbial plate count (squares), LAB, lactic acid bacteria count (up-pointing triangles), and yeast plate counts (down-pointing triangles) in colony forming units per millilitre (CFU mL<sup>-1</sup>), cycle threshold (Ct) values for the number of cycles required to exceed the background for the qPCR of the bacterial 16S rRNA gene have been indicated on the inverted right y-axis (diamonds). The X-axis displays the time in hours after the addition of the starter culture (SC). Raw milk (RM) is equivalent to the fermented product at time = 0 hours. The data for 0 to 24 hours (1 day) refer to raw milk fermentation at 28 °C, followed by storage at 4 °C from 1 day to three weeks. Data for heated milk kefir (HMK) obtained by 24 hours of fermentation at 28 °C have been indicated by open symbols.

higher levels of yeasts ( $0.8 \times 10^6$  CFU mL<sup>-1</sup>) than RMK ( $0.2 \times 10^5$  CFU mL<sup>-1</sup>) after one day of fermentation at 28 °C. The significance of differences in CFU counts between RMK and HMK was confirmed by including enumeration results of a kefir batch fermented from different raw milk, leading to *p*-values of 0.5 (total bacteria), 0.4 (lactic acid bacteria) and 0.03 (yeasts). During storage of bottled RMK at 4 °C from 24 hours to three weeks, a reduction of CFU count of lactic acid bacteria was observed, while the CFU count of yeasts further increased during this period.

### 3.2. Composition of microbiota during fermentation and storage of raw milk kefir

**3.2.1. Drastic reduction of microbial species richness during fermentation.** Analysis of the amplicon sequence variants (ASVs) of the starter culture (SC) led to the identification of eleven microbial ASVs, belonging to four bacterial species and one fungal ASV, including the bacteria *Streptococcus thermophilus*, *Lactococcus lactis*, *Lactococcus*, *Leuconostoc* and yeast *Debaryomyces* (Fig. 4). These microbial species coincide with the five microbial species declared on the label of the used kefir starter culture. RM and HM both showed an extremely high richness of over 100 microbial species (ESI 1<sup>+</sup>). However, it should be noted that the total viable count of bacteria and fungi in the RM was limited to values of only 10<sup>3</sup> and 10<sup>2</sup> CFU



**Fig. 4** Logarithmic bar chart of the microbial composition during fermentation and storage of raw milk kefir. (A) The relative number amplicon sequence variants (ASVs) determined by the bacterial V3-V4 region of the 16S rRNA gene amplicon, and (B) the fungal ITS1 region. Genus and species names have been indicated in italics. The numbers behind the species names correspond to the number of observed unique ASVs. The label cat indicates that multiple ASVs have been concatenated to a single annotation. The Y-axis displays relative abundance in the logarithmic order. The X-axis displays samples with time after the addition of the starter culture. SC = defined starter culture. HMK = heated milk kefir after 24 hours of fermentation. Dashed lines indicate ASVs, which are not present in the starter culture and could originate from raw milk. Horizontal lines indicate ASVs that were assigned to species present in the spike-in. Chequered bars indicate microbial species that do not originate from RM.



mL<sup>-1</sup>, respectively (Fig. 3). The process of kefir fermentation reduced the microbial richness in the sample to 10 abundant microbial species. After the first 12 hours of fermentation there was a limited change in composition, both in bacteria and in fungi (Fig. 4 and ESI 2†). From this time point, the bacterial and fungal microbiota composition in the kefir is predominantly described by the ASVs that represent the five microbial species of the starter culture.


**3.2.2. Unique bacterial and fungal species in raw milk kefir.** Further inspection of the data led to the identification of several bacterial and fungal species, which were present in RMK samples, but absent in HMK samples (Fig. 4 and ESI 2†). Strikingly, all RMK samples from the end-product on the first day to three weeks contained bacterial ASVs of *Lactococcus lactis* (ASV # 3; 0.6%), *Lactococcus* (ASV # 7; 0.8%), both of which were absent in HMK. Although the relative abundances of the latter ASVs were low, the overall bacterial load has increased by five orders of magnitude to 10<sup>8</sup> CFU mL<sup>-1</sup>, leading to the substantial presence of these bacteria in the final raw milk kefir products. In addition, ASVs from the yeasts *Pichia kudriavzevii* (12%) and *Galactomyces* (2.3%) could be identified in the final RMK products, but not in HMK. These two yeasts unique to raw milk kefir were represented by three and six distinct ASVs, respectively, while all the abundant bacterial and fungal ASVs identified in HMK were limited to those present in the starter culture. Minor amounts of the bacterium *Streptococcus dysgalactiae* were present in raw milk and RMK products as well, the yeasts *Malassezia restricta* and *Malassezia globosa*. Finally, a few bacterial and fungal species could be

identified as contaminants, including the bacterial genus *Burkholderia* and the yeast *Erythrobasidium hasegawianum*, which were present in milk with low overall microbial loads, but decreased during the process of fermentation and could not be identified in the final products.

### 3.3. Composition of peptides in milk and kefir end products


**3.3.1. Fermentation increases the number of peptides in kefir.** Peptide analysis resulted in the identification of 2525 different bovine peptides, of which 478 peptides were identified in all samples (Fig. 5A). In addition, 1039 peptides were only identified in kefir samples and 202 peptides were only found in milk, showing that fermentation of the milk results in a drastic increase in the number of unique peptides. This also holds for the total abundance of the peptides, which was several magnitudes higher in the kefir samples (Fig. 5B). Most of the peptides formed during fermentation have a length shorter than 20 amino acids (Fig. 6). RM and RMK have a higher number of unique peptides when compared to HM and HMK, respectively (Fig. 5A). Nevertheless, the total peptide intensity was higher in HMK than in RMK (Fig. 5B).

**3.3.2. Most kefir peptides originate from caseins.** Regarding the precursor proteins, it can be noted that most peptides originate from caseins. This holds for both the number of peptides only identified in kefir (Table 1) and the peptide intensity (Fig. 6 and ESI 3†). Fermentation of the milk causes a notable increase in the number of unique peptides and the intensity of peptides from caseins, glycosylation-



**Fig. 5** (A) UpSet plot visualizing the intersections of identified peptides in different samples. Vertical bars represent the number of unique peptides identified in the intersection of samples shown underneath each bar. Horizontal bars represent the total number of peptides identified in each sample. Box plots underneath each section show the peptide lengths in the respective section. (B) Total peptide intensity per sample. With raw milk (RM), heated milk (HM), raw milk kefir (RMK), and heated milk kefir (HMK).





**Fig. 6** Bar plots of summed peptide intensity per binned range of peptide lengths. With peptides from (A) caseins and (B) whey proteins.

**Table 1** Precursor proteins of kefir peptides with the number of identified peptides in raw milk (RM), heated milk (HM), raw milk kefir (RMK), and heated milk kefir (HMK). Shown are proteins with at least 5 identified peptides in one of the 4 samples, arranged on the number of identified peptides in RM. Colour gradient represents high numbers (green) to low numbers (red) of unique peptides

Protein name	RM	HM	RMK	HMK
β-Casein	288	239	658	619
α <sub>S1</sub> -Casein	252	246	342	336
α <sub>S2</sub> -Casein	177	158	260	251
Glycosylation-dependent cell adhesion molecule 1	94	82	216	184
κ-Casein	93	67	392	385
Polymeric immunoglobulin receptor	30	29	65	62
Butyrophilin subfamily 1 member A1	24	25	23	17
Sodium-dependent phosphate transport protein 2B	22	19	20	19
Perilipin-2	15	15	14	8
Osteopontin	9	10	65	56
β-Lactoglobulin	7	10	6	9
Glycoprotein 2	7	7	1	3
Lactoperoxidase	5	5	2	3
β-2-Microglobulin	0	0	14	12
Nucleobindin-1	0	0	9	6


dependent cell adhesion molecule 1 (Glycam-1), osteopontin, and polymeric immunoglobulin receptor (PIGR).

**3.3.3. Raw milk kefir shows a higher number of bioactive peptides.** Whey peptides with a length up to 30 amino acids are more abundant in RMK than in HMK, whereas the opposite is true for peptides from caseins (Fig. 6). Nevertheless, regarding peptides longer than 30 amino acids, peptides from whey proteins are more abundant in HMK than in RMK and again, the opposite is observed for peptides from caseins. Next, the presence of bioactive peptides was determined and their intensities in RMK and HMK were compared (ESI 4†). The most frequently found bioactivities were ACE-inhibitory, antioxidant, and antimicrobial activity. Comparing HMK with RMK, showed that HMK comprises a larger number of bioactive sequences that are more abundant in HMK than in RMK. Comparing bioactivities of peptides identified uniquely in either HMK or RMK, showed that RMK has a larger number of bioactive peptides.

### 3.4. Murine food allergy model

**3.4.1. Treatment with RMK suppressed the acute allergic skin response.** In mice treated with PBS, sensitisation with OVA (PBS/OVA) resulted in an acute allergic skin response (Fig. 7A), and anaphylactic shock symptoms (Fig. 7C) upon i.d. challenge compared to PBS/PBS mice. Sensitised mice treated with RMK (RMK/OVA) showed a reduced acute allergic skin response compared to PBS/OVA allergic mice. Although the anaphylactic shock score was lower in RMK/OVA mice, no significant effects were observed on anaphylactic shock symptoms and body temperature compared to PBS/OVA mice. Sensitised mice treated with HMK (HMK/OVA) showed no effect on the acute allergic skin response indicating that heating of milk before fermentation affected the protective effect of kefir.

**3.4.2. Increased levels of OVA-specific IgE levels in mice treated with HMK.** Allergic symptoms are predominantly mediated *via* allergen specific IgE. Therefore OVA-specific IgE and -IgG1 levels were measured in serum 16 hours after oral challenge. OVA-specific IgE levels were increased in PBS/OVA allergic mice compared to PBS/PBS sham sensitised mice (Fig. 7B). Although not significantly different, low levels OVA-IgE were observed in the RMK/OVA mice and higher levels in the HMK/OVA mice. In contrast to RMK/OVA mice, OVA-IgE levels were significantly increased in HMK/OVA mice compared



**Fig. 7** Reduced acute allergic skin response upon OVA challenge in mice treated with RMK. (A) The acute allergic skin response measured as  $\Delta$  ear swelling 1 h after i.d. challenge, (B) OVA-specific IgE, (C) anaphylactic shock score. Data are presented as mean  $\pm$  SEM for the acute allergic skin response, as box-and-whisker Tukey plot for OVA-IgE and as individual data points for anaphylactic shock scores,  $n = 6$  in the PBS group and  $n = 8$  in all other groups.  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ , as analysed by one-way ANOVA followed by Bonferroni's multiple comparisons test for pre-selected groups (A) or Kruskal–Wallis test for non-parametric data followed by Dunn's multiple comparisons test for pre-selected groups (B and C). OVA = ovalbumin; RMK = raw milk kefir; HMK = heated milk kefir; i.d. = intradermal; n.s. = not significantly different.





to PBS/PBS mice. No effect on OVA-IgG1 was observed in sensitised mice treated with RMK or HMK (data not shown).

**3.4.3. Decreased activated Th1-cells and IFN $\gamma$  production after treatment with HMK.** To further determine the local effects of the kefir treatments, T-cell subsets in MLN and cytokine production in the spleen were studied. Percentages of activated Th2- and Th1-cells were not affected in PBS/OVA mice when compared to PBS/PBS mice (Fig. 8A and C). Interestingly, HMK/OVA mice showed a reduction in activated Th1-cell percentages in MLN with no effects on the percentages of activated Th2-cells. The effect on activated Th1 cells was supported by reduced IFN $\gamma$  production in splenocytes after *ex vivo* stimulation with OVA (Fig. 8B). In line with the presented data on percentages of activated Th2 cells (Fig. 8C), we did not observe differences in the *ex vivo* IL-5 cytokine response in mice treated with RMK or HMK (Fig. 8D). No effect was

observed on Foxp3+ regulatory T-cells (Fig. 8E), indicating that a shift in Th2/Th1 balance is underlying the protective effects.


## 4. Discussion

The safety of the RMK is based on two principles, a high hygienic standard during milking and processing as well as the immediate acidification of raw milk. In several countries, legal raw milk has been produced under very strict hygienic conditions. The zoonotic risk is almost reduced to zero, and if any zoonotic bacteria were detected, there were no adverse health effects found by the authorities.<sup>39</sup> As a result of the high hygienic standards applied at the dairy farm delivering raw milk for this study, the bacterial contamination of the raw milk is kept around and below  $10^3$  CFU mL<sup>-1</sup>. Furthermore, there was a very short period between the end of milking and the start of culturing for less than two hours, leading to the rapid production of lactic acid, resulting in a lowering of the pH to 4.3, limiting the risk for microbial contamination and foodborne diseases,<sup>40,41</sup> also in raw fermented milk.<sup>42</sup>

After 24 h of fermentation with the added SC, kefir contains approximately  $10^8$  bacteria and  $10^5$  yeasts per mL. This agrees with previous reports, indicating ranges of lactic acid bacteria between  $10^8$  and  $10^9$  CFU mL<sup>-1</sup> and for the yeast of  $10^5$  and  $10^6$  CFU mL<sup>-1</sup> in the final kefir products.<sup>43</sup> With respect to storage, we observed a further increase of yeast counts over the period of three weeks, while the lactic acid bacteria reached their highest levels after one day of fermentation and the numbers started to decline during storage, possibly due to further acidification. Indeed, other studies confirmed a slight decrease in lactic acid bacteria and an increase of yeasts in kefir produced from a starter culture stored over a period of three weeks.<sup>44</sup> Strikingly, HMK showed higher levels of fungi than RMK after one day of fermentation. This could result from the inactivation of the antifungal lactobacilli known to be present in RM.<sup>45</sup>

Most of the detected microbial amplicons are identical to or are derived from the added SC and could be considered as safe or even beneficial for consumption. Although human infections with food derived yeasts harbouring virulence factors such as those seen in some food derived from *Kluyveromyces marxianus* are potentially possible.<sup>46</sup> *Streptococcus dysgalactiae* was detected in RM. It is most frequently encountered as a human commensal of the alimentary tract or genital tracts, and exposure to it could contribute to trained immunity.<sup>47</sup>

Both RM and HM showed a very high richness of over one hundred microbial species. As these species have been identified based on their DNA in RM, this number may overrepresent the number of viable microbial species in the milk. Previous studies also led to the detection of hundreds of bacterial species in the RM microbiota. In agreement with the present study, members of the phyla Firmicutes and Proteobacteria account for most of these species.<sup>48</sup> Their abundance depends on specific environmental conditions. In our



**Fig. 8** Decreased percentages of activated Th1-cells and IFN $\gamma$  production in mice treated with HMK. Percentages of (A) activated Th1 cells (CxCR3 of CD4+ CD69+ cells) in MLN, (B) concentration of IFN $\gamma$  in *ex vivo* OVA stimulated splenocytes, (C) activated Th2 cells (T1ST2+ of CD4+ CD69+ cells), (D) concentrations of IL-5 in *ex vivo* OVA stimulated splenocytes, and (E) Foxp3+ regulatory T-cells in MLN. Data are presented as mean  $\pm$  SEM,  $n = 6$  in the PBS group and  $n = 8$  in all other groups. \*\* $P < 0.01$  as analysed by one-way ANOVA followed by Bonferroni's multiple comparisons test for pre-selected groups. \*\*\* $P < 0.001$  with Kruskal–Wallis test for non-parametric data followed by Dunn's multiple comparisons test for pre-selected groups. OVA = ovalbumin; RMK = raw milk kefir; HMK = heated milk kefir; MLN = mesenteric lymph nodes.



fresh raw milk microbiota, we found a rather even distribution of microbial species, in contrast to other studies where the milk-fermenting species *Streptococcus thermophilus* and *Lactococcus lactis* dominated the raw milk microbiota.<sup>49</sup> The numbers of detected fungi were limited in our raw milk to about 30 ASVs, including yeasts *Debaryomyces*, *Mallasezia*, and *Candida* and the mold *Cladosporium*, all previously detected members of the raw milk mycobiota with a potential role in milk fermentation as some of them are efficient lactose degraders and show proteolytic and lipolytic activity.<sup>48</sup> During the process of fermentation, the richness in microbial species drastically reduced. The most prominent members include the bacteria *Streptococcus thermophilus*, *Lactococcus lactis*, *Lactococcus*, *Leuconostoc* and the yeast *Debaryomyces* showing a perfect ASV match to those of the microbial species present in the defined kefir starter culture. It should be noted that the kefir fermentation with a defined starter culture reported here is rather different from the kefir fermentation with natural grains, which includes a bacterial core community consisting of the kefir matrix former *Lactobacillus kefirianofaciens* and *Lactobacillus kefir*, *Leuconostoc* sp., *Lactococcus lactis* and *Acetobacter* sp.<sup>3</sup> In the latter case a niche has been created by early fermenters by the production of amino acids and lactate, which is converted to acetic acid by *Acetobacter* sp. Although the last process appears to be absent in our raw milk kefir production, as we did not identify any acetic acid bacteria, we did identify bacteria and yeasts that were not detectable or at low levels in early kefir fermentation and were more predominantly present after 6 to 12 hours of fermentation. These late fermenting microbial species included a specific variant of *L. lactis* and species of the fungi *Galactomyces* and *Pichia*. The former possibly uses galactose produced from lactose,<sup>50</sup> while the latter species may be involved in proteolytic activity.<sup>51</sup>

The production of kefir from raw milk produced in this study raises the question of whether the raw milk microbiota participates in the kefir fermentation process. A comparative analysis of the microbiota from heated milk kefir indicates that several ASVs identified in raw milk kefir were absent in heated milk kefir. These ASVs match specific variants of the *L. lactis* and the fungus *Galactomyces geotrichum* and yeast *Pichia kudriavzevii*. It should be noted that the latter two species also have been identified in raw milk which has been used for fermentation, whereas the variants of *L. lactis* were possibly below the detection limit. Interestingly, co-cultures of *Galactomyces geotrichum* or *Pichia kudriavzevii* with *Lactobacillus* sp. showed a strong stimulating effect on the production of peptides.<sup>51</sup> These peptides include bioactive anti-hypertensive peptides<sup>52</sup> with a strong activity against Angiotensin I-Converting Enzyme (ACE), a dipeptidyl carboxypeptidase that plays a role in the regulation of blood pressure.<sup>53</sup> In addition, the presence of wild *L. lactis* strains in raw milk kefir could increase bioactive peptide levels in the final product.<sup>54</sup>

The main result emerging from the peptide analysis is that upon fermentation, the number of unique peptides and the total peptide abundance increases by several orders of magni-

tude (Fig. 5). This increase results from the proteolytic degradation either by endogenous or microbial proteolytic enzymes. The microbial proteases may originate from both the defined starter culture for both types of kefir and the raw milk specifically for the RMK samples.<sup>7</sup> Both before and after fermentation, most of the peptides were derived from the hydrolysis of caseins, especially  $\beta$ -casein (Table 1). The majority of peptides has a length of less than 20 amino acids, as observed in previous studies of kefir peptides.<sup>55,56</sup> For endogenous milk proteases like plasmin, it is known that caseins are their major target.<sup>57</sup> Also, for lactic acid bacteria, it is known that their proteases preferentially hydrolyse caseins.<sup>58</sup> Interestingly, additional bioactive peptides may be formed by the unique co-cultures of *Galactomyces geotrichum* or *Pichia kudriavzevii* with *Lactobacillus* sp. originating from raw milk, as discussed above.<sup>51</sup> Many peptides present in milk were not identified after fermentation to kefir (Fig. 5A), as 202 peptides were only found in the milk samples. The most probable explanation would be that these peptides are further degraded upon fermentation, leading to the formation of shorter peptides or free amino acids. This is underpinned by the peptide length data in Fig. 5A, which shows that these 202 peptides present only in unfermented milk were on average longer than the peptides present only in kefir, or in both kefir and milk. When looking at the amino acids in the P1 and P1' positions of the peptides (ESI 5<sup>+</sup>), there is a difference in cleavage specificity between RMK and HMK. However, as the proteases produced by the unique cultures in RMK are not characterized, it is not possible to determine whether there is a direct relation.

A comparative analysis of RMK and HMK showed that the number of unique peptides was higher in RMK than in HMK (172 vs. 125; Fig. 5A). This may be explained by the larger diversity in the microbiota of RMK (Fig. 4), which could have led to proteolysis by a larger set of different proteases with different cleavage site specificities. In particular, the presence of additional *Lactococcus lactis* or fungal strains in RMK may play a role, as it is known that these species produce a wide range of proteases and peptidases that will cleave casein at many different cleavage sites, leading amongst others to the formation of so-called peptide ladders,<sup>59</sup> which were also found in our peptidomics dataset.

As studies on the digestion of whey proteins have shown that denatured whey proteins are generally digested faster,<sup>60</sup> we expected the HMK to contain a larger amount of whey protein-derived peptides. However, our data (Table 1 and Fig. 6) do not confirm this hypothesis. As the sample underwent a short boiling step, which is a rather intense heat treatment, more extensive whey protein aggregation than during low pasteurisation may have occurred. It has previously been shown that the effect of whey protein digestion depends on the specific aggregation structure<sup>61</sup> and that intense heating may reduce whey protein proteolysis during fermentation.<sup>62</sup> The specific, rather intense, heat treatment used in this study, may thus be the reason why no increase in whey protein-derived peptides was found in the HMK sample.



Nevertheless, although HMK showed to have less unique peptides than RMK, the total peptide abundance was higher. This is in line with the finding that proteolysis in HMK is carried out by a less diverse set of proteases, with less variation in cleavage specificity, leading to a less diverse peptide profile.

A search for known bioactivities showed that HMK has a higher bioactive potential than RMK when peptide abundances are considered (ESI 4†). Nevertheless, for peptides that were identified only in HMK or RMK, most bioactive sequences were found in RMK. Although this could indicate a difference in the effect that HMK and RMK can have on health, caution is needed in interpretation since the extent of bioactivity is different for each peptide. Therefore, it is not possible to speculate on the role of specific peptides in the allergy-modulating effect of RMK.

In this study we show for the first time the protective effect of kefir on the food allergic response towards a food allergen. The outcomes are in accordance with the experiences in adults, consuming raw milk kefir. In a retrospective study, people experienced an improved score for their health, immunity, bowel, and mood after regular consumption of raw milk kefir, and health improvements were the largest among people mentioning a poor health.<sup>63</sup> In the current pre-clinical study, beneficial anti-allergic effects are only observed in kefir produced from raw, unprocessed milk. A reduced acute allergic skin response is observed in RMK, but not in the kefir prepared from heated milk (HMK). The acute allergic skin response resembles the skin prick test in humans used to identify sensitisation to specific allergens. Previous studies showed health benefits in relation to reduced inflammation and airway hyperresponsiveness in murine allergic asthma models.<sup>13,64</sup> In those studies, kefir from pasteurised milk was used. The current study shows that only RMK possesses the putative capacity to redirect the food allergic response to the unrelated food allergen ovalbumin. Allergen-specific IgE is one of the key biomarkers responsible for the induction of allergic symptoms. Specific IgE is produced after sensitisation, *i.e.*, the first encounter with the food allergen. Then IgE specifically binds to a high-affinity Fc receptor on the surface of mast cells or basophils that binds to allergen epitopes and triggers the release of inflammatory mediators and as a result the induction of food allergic symptoms. Although the effects of milk fermentation have been studied,<sup>65–67</sup> only one study describes kefir related effects on food sensitisation. Hong *et al.* showed suppression of IgE production and modulation of the T-cell compartment in LAB, *Lactobacillus kefirianofaciens* M1 treated mice.<sup>68</sup> However, they did not investigate kefir as a matrix and the measurement of clinically related symptoms were not included in the study. Although no difference was observed in OVA-IgE between RMK and HMK in the current study, higher OVA-specific IgE levels in HMK treated allergic mice compared to control mice might underly the protective effect of RMK. One of the main mechanisms leading to a heightened IgE response in food allergy is an imbalance in the Th1/Th2 cells.<sup>69–71</sup> The allergy protective effect of RMK was related to a changed Th1/Th2 ratio as shown as an increase in activated

Th1-cell percentages in mesenteric lymph nodes and splenic IFN $\gamma$  production in RMK treated mice (Fig. 8). Differences were limited to the Th1 cells, no effect of kefir was observed on the percentage of activated Th2 cells nor their cytokine IL-5. The change in the Th1/Th2 ratio may be in part due to the increased number of regulatory T-cells. However, regulatory T-cell percentages are not changed in the current study. It should be noted that the applied milk heat treatment was at a higher temperature for the HMK used for the microbiota analysis and peptidomics than the HMK sample used for the murine allergy model in this study. However, this will not affect our conclusions on differences between RMK and HMK, because HMK served as a 'negative control' in our allergy model experiments.

## 5. Conclusions

The raw milk kefir made in this study was assumed to be safe based on high hygienic standards and immediate milk acidification. The *overall* microbial composition of raw milk kefir resembled that of the defined starter culture. In addition, raw milk kefir contained specific bacterial strains and yeasts which could not be identified in heated milk kefir. Their proteolytic activity may be responsible for the wider range of peptides identified and associated bioactivities in raw milk compared to heated milk kefir. In line with these results, raw milk kefir reduced the acute allergic skin response and modulated T-cell responses in a murine food allergy model.

## Abbreviations

ASV	Amplicon sequence variant
cat	Concatenated
CFU	Colony forming unit
Ct	Cycle threshold
SC	Defined starter culture eXact® 2 kefir, Chr. Hansen
EV	Extracellular vesicles
ITS	Internal transcribed spacer
NCBI	National Centre for Biotechnology Information
PBS	Phosphate buffered saline solution
HM	Heated milk (shortly boiled)
HMK	Heated milk kefir based on SC
qPCR	Quantitative real-time polymerase chain reaction
RA	Relative abundance
RM	Raw milk
RMK	Raw milk kefir based on SC

## Author contributions

TB brought the research partners together. TB, BvE, KH, JG and RK designed the research. TB, BvE, ZZ, PD, LvO, SB and MD conducted the research. BvE, ZZ, LvO and PD analysed the data. TB, BvE, KH, PD and RK wrote the paper. RK carried out



the final editing of the manuscript. All authors read and approved the final manuscript.

## Conflicts of interest

TB is partly sponsored for his research activity by the Raw Milk Company. JG and BvE are partly employed at Danone Nutricia Research. All other authors report no conflict of interest.

## Acknowledgements

Software AG Stiftung, Darmstadt, Germany is acknowledged for funding the murine allergy study. Raw Milk Company, De Lutte, The Netherlands is acknowledged for providing the milk and kefir samples in this study as well as funding for the microbial enumeration experiments. Funding for microbiota profiling was obtained by R. K. from his NPN James Lind Award 2018.

## References

- J. P. Tamang, P. D. Cotter, A. Endo, N. S. Han, R. Kort, S. Q. Liu, *et al.*, Fermented foods in a global age: East meets West, *Compr. Rev. Food Sci. Food Saf.*, 2020, **19**(1), 184–217.
- W. Gao, L. Zhang, Z. Feng, H. Liu, N. Shigwedha, X. Han, *et al.*, Microbial diversity and stability during primary cultivation and subcultivation processes of Tibetan kefir, *Int. J. Food Sci. Technol.*, 2015, **50**(6), 1468–1476.
- S. Blasche, Y. Kim, R. A. T. Mars, D. Machado, M. Maansson, E. Kafkia, *et al.*, Metabolic cooperation and spatiotemporal niche partitioning in a kefir microbial community, *Nat. Microbiol.*, 2021, **6**(2), 196–208.
- D. E. Kioussi, N. Choriantopoulos, C. C. Tassou and A. Galanis, The clash of microbiomes: from the food matrix to the host gut, *Microorganisms*, 2022, **10**(1), 116.
- M. L. Marco, D. Heeney, S. Binda, C. J. Cifelli, P. D. Cotter, B. Foligné, *et al.*, Health benefits of fermented foods: microbiota and beyond, *Curr. Opin. Biotechnol.*, 2017, **44**, 94–102.
- J. Ebner, A. Aşçi Arslan, M. Fedorova, R. Hoffmann, A. Küçükçetin and M. Pischetsrieder, Peptide profiling of bovine kefir reveals 236 unique peptides released from caseins during its production by starter culture or kefir grains, *J. Proteomics*, 2015, **117**, 41–57.
- D. C. Dallas, F. Citerne, T. Tian, V. L. M. Silva, K. M. Kalanetra, S. A. Frese, *et al.*, Peptidomic analysis reveals proteolytic activity of kefir microorganisms on bovine milk proteins, *Food Chem.*, 2016, **197**, 273–284.
- B. C. T. Bourrie, B. P. Willing and P. D. Cotter, The microbiota and health promoting characteristics of the fermented beverage kefir, *Front. Microb.*, 2016, **7**, 647.
- D. H. Kim, D. Jeong, H. Kim and K. H. Seo, Modern perspectives on the health benefits of kefir in next generation sequencing era: Improvement of the host gut microbiota, *Crit. Rev. Food Sci. Nutr.*, 2019, **559**, 1782–1793.
- C. Slattery, P. D. Cotter and P. W. O'Toole, Analysis of health benefits conferred by *Lactobacillus* species from kefir, *Nutrients*, 2019, **11**(6), 1252.
- M. A. Farag, S. A. Jomaa, A. A. El-wahed and H. R. El-seedi, The many faces of kefir fermented dairy products: Quality characteristics, flavour chemistry, nutritional value, health benefits, and safety, *Nutrients*, 2020, **12**(2), 346.
- N. F. Azizi, M. R. Kumar, S. K. Yeap, J. O. Abdullah, M. Khalid, A. R. Omar, *et al.*, Kefir and its biological activities, *Foods*, 2021, **10**(6), 1210.
- M. Y. Lee, K. S. Ahn, O. K. Kwon, M. J. Kim, M. K. Kim, I. Y. Lee, *et al.*, Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model, *Immunobiology*, 2007, **212**(8), 647–654.
- M. Tanaka and J. Nakayama, Development of the gut microbiota in infancy and its impact on health in later life, *Allergol. Int.*, 2017, **66**(4), 515–522.
- A. K. Adiloğlu, N. Gönülateş, M. İşler and A. Şenol, The effect of kefir consumption on human immune system: a cytokine study, *Mikrobiyol. Bul.*, 2013, **47**(2), 273–281.
- K. Thoreux and D. L. Schmucker, Kefir milk enhances intestinal immunity in young but not old rats, *J. Nutr.*, 2001, **131**(3), 807–812.
- T. Brick, M. Ege, S. Boeren, A. Böck, E. von Mutius, J. Vervoort, *et al.*, Effect of processing intensity on immunologically active bovine milk serum proteins, *Nutrients*, 2017, **9**(9), 1–14.
- E. Kontopodi, S. Boeren, B. Stahl, J. B. van Goudoever, R. M. van Elburg and K. Hettinga, High-temperature short-time preserves human milk's bioactive proteins and their function better than pasteurization techniques with long processing times, *Front. Pediatr.*, 2022, **9**, 798609.
- M. C. Michalski and C. Januel, Does homogenization affect the human health properties of cow's milk?, *Trends Food Sci. Technol.*, 2006, **17**(8), 423–437.
- C. Braun-Fahrlander and E. von Mutius, Can farm milk consumption prevent allergic diseases?, *Clin. Exp. Allergy*, 2011, **41**(1), 29–35.
- G. Loss, S. Apprich, M. Waser, W. Kneifel, J. Genuneit, G. Büchele, *et al.*, The protective effect of farm milk consumption on childhood asthma and atopy: The GABRIELA study, *J. Allergy Clin. Immunol.*, 2011, **128**(4), 766–773.
- S. Abbring, J. T. Ryan, M. A. P. Diks, G. Hols, J. Garssen and B. C. A. M. van Esch, Suppression of food allergic symptoms by raw cow's milk in mice is retained after skimming but abolished after heating the milk—A promising contribution of alkaline phosphatase, *Nutrients*, 2019, **11**(7), 1499.
- S. Abbring, L. Xiong, M. A. P. Diks, T. Baars, J. Garssen, K. Hettinga, *et al.*, Loss of allergy-protective capacity of raw cow's milk after heat treatment coincides with loss of immunologically active whey proteins, *Food Funct.*, 2020, **11**(6), 4982–4993.



- 24 S. Abbring, D. Kusche, T. C. Roos, M. A. P. Diks, G. Hols, J. Garssen, *et al.*, Milk processing increases the allergenicity of cow's milk—Preclinical evidence supported by a human proof-of-concept provocation pilot, *Clin. Exp. Allergy*, 2019, **49**(7), 1013–1025.
- 25 E. Bolyen, J. R. Rideout, M. R. Dillon, N. A. Bokulich, C. C. Abnet, G. A. Al-Ghalith, *et al.*, Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, *Nat. Biotechnol.*, 2019, **37**(8), 852–857.
- 26 B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han, A. J. A. Johnson and S. P. Holmes, DADA2: High-resolution sample inference from Illumina amplicon data, *Nat. Methods*, 2016, **13**(7), 581–583.
- 27 C. Quast, E. Pruesse, P. Yilmaz, J. Gerken, T. Schweer, P. Yarza, *et al.*, The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, *Nucleic Acids Res.*, 2012, **41**(D1), D590–D596.
- 28 R. H. Nilsson, K. H. Larsson, A. F. S. Taylor, J. Bengtsson-Palme, T. S. Jeppesen, D. Schigel, *et al.*, The UNITE database for molecular identification of fungi: handling dark taxa and parallel taxonomic classifications, *Nucleic Acids Res.*, 2019, **47**(D1), D259–D264.
- 29 <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA716278>.
- 30 J. Lu, S. Boeren, S. C. de Vries, H. J. F. van Valenberg, J. Vervoort and K. Hettinga, Filter-aided sample preparation with dimethyl labeling to identify and quantify milk fat globule membrane proteins, *J. Proteomics*, 2011, **75**(1), 34–43.
- 31 K. A. Dingess, M. de Waard, S. Boeren, J. Vervoort, T. T. Lambers, J. B. van Goudoever, *et al.*, Human milk peptides differentiate between the preterm and term infant and across varying lactational stages, *Food Funct.*, 2017, **8**(10), 3769–3782.
- 32 Y. Liu, A. de Groot, S. Boeren, T. Abee and E. J. Smid, Lactococcus lactis mutants obtained from laboratory evolution showed elevated vitamin K2 content and enhanced resistance to oxidative stress, *Front. Microbiol.*, 2021, **12**, 746770.
- 33 J. Cox and M. Mann, MaxQuant enables high peptide identification rates, individualized ppb-range mass accuracies and proteome-wide protein quantification, *Nat. Biotechnol.*, 2008, **26**(12), 1367–1372.
- 34 A. Bateman, M. J. Martin, S. Orchard, M. Magrane, R. Agivetova, S. Ahmad, *et al.*, UniProt: the universal protein knowledgebase in 2021, *Nucleic Acids Res.*, 2021, **49**(D1), D480–D489.
- 35 P. M. Dekker, S. Boeren, A. H. Wijga, G. H. Koppelman, J. J. M. Vervoort and K. A. Hettinga, Maternal allergy and the presence of nonhuman proteinaceous molecules in human milk, *Nutrients*, 2020, **12**, 1169.
- 36 S. D. Nielsen, R. L. Beverly, Y. Qu and D. C. Dallas, Milk bioactive peptide database: A comprehensive database of milk protein-derived bioactive peptides and novel visualization, *Food Chem.*, 2017, **232**, 673–682.
- 37 O. Wagih, ggseqlogo: a versatile R package for drawing sequence logos, *Bioinformatics*, 2017, **33**(22), 3645–3647.
- 38 X. M. Li, B. H. Schofield, C. K. Huang, G. I. Kleiner and H. A. Sampson, A murine model of IgE-mediated cow's milk hypersensitivity, *J. Allergy Clin. Immunol.*, 1999, **103**(2 Pt 1), 206–214.
- 39 A. C. Berge and T. Baars, Raw milk producers with high levels of hygiene and safety, *Epidemiol. Infect.*, 2020, **148**, e14.
- 40 L. O'Sullivan, R. P. Ross and C. Hill, Potential of bacteriocin-producing lactic acid bacteria for improvements in food safety and quality, *Biochimie*, 2002, **84**(5–6), 593–604.
- 41 M. J. R. Nout, Fermented foods and food safety, *Food Res. Int.*, 1994, **27**(3), 291–298.
- 42 S. Schoustra, C. van der Zon, A. Groenenboom, H. B. Moonga, J. Shindano, E. J. Smid, *et al.*, Microbiological safety of traditionally processed fermented foods based on raw milk, the case of Mabisi from Zambia, *LWT*, 2022, 113997.
- 43 C. Hecer, B. Ulusoy and D. Kaynarca, Effect of different fermentation conditions on composition of kefir microbiota, *Int. Food Res. J.*, 2019, **26**, 401–409.
- 44 T. Kök-Taş, A. C. Seydim, B. Özer and Z. B. Guzel-Seydim, Effects of different fermentation parameters on quality characteristics of kefir, *J. Dairy Sci.*, 2013, **96**(2), 780–789.
- 45 E. Delavenne, J. Mounier, F. Déniel, G. Barbier and G. le Blay, Biodiversity of antifungal lactic acid bacteria isolated from raw milk samples from cow, ewe and goat over one-year period, *Int. J. Food Microbiol.*, 2012, **155**(3), 185–190.
- 46 L. Pérez-Través, R. de Llanos, A. Flockhart, L. García-Domingo, M. Groenewald, R. Pérez-Torrado, *et al.*, Virulence related traits in yeast species associated with food; *Debaryomyces hansenii*, *Kluyveromyces marxianus*, and *Wickerhamomyces anomalus*, *Food Control*, 2021, **124**, 107901.
- 47 M. G. Netea, J. Domínguez-Andrés, L. B. Barreiro, T. Chavakis, M. Divangahi, E. Fuchs, *et al.*, Defining trained immunity and its role in health and disease, *Nat. Rev. Immunol.*, 2020, **20**, 375–388.
- 48 L. Quigley, O. O'Sullivan, C. Stanton, T. P. Beresford, R. P. Ross, G. F. Fitzgerald, *et al.*, The complex microbiota of raw milk, *FEMS Microbiol. Rev.*, 2013, **37**(5), 664–698.
- 49 W. Masoud, F. K. Vogensen, S. Lillevang, W. Abu Al-Soud, S. J. Sørensen and M. Jakobsen, The fate of indigenous microbiota, starter cultures, *Escherichia coli*, *Listeria innocua* and *Staphylococcus aureus* in Danish raw milk and cheeses determined by pyrosequencing and quantitative real time (qRT)-PCR, *Int. J. Food Microbiol.*, 2012, **153**(1–2), 192–202.
- 50 A. R. Neves, W. A. Pool, A. Solopova, J. Kok, H. Santos and O. P. Kuipers, Towards enhanced galactose utilization by *Lactococcus lactis*, *Appl. Environ. Microbiol.*, 2010, **76**(21), 7048–7060.
- 51 C. Chaves-López, A. Serio, A. Paparella, M. Martuscelli, A. Corsetti, R. Tofalo, *et al.*, Impact of microbial cultures on proteolysis and release of bioactive peptides in fermented milk, *Food Microbiol.*, 2014, **42**, 117–121.



- 52 B. Hernández-Ledesma, B. Miralles, L. Amigo, M. Ramos and I. Recio, Identification of antioxidant and ACE-inhibitory peptides in fermented milk, *J. Sci. Food Agric.*, 2005, **85**(6), 1041–1048.
- 53 J. F. Riordan, Angiotensin-I-converting enzyme and its relatives [Internet], *Genome Biol.*, 2003, **4**(8), 225.
- 54 J. C. Rodríguez-Figueroa, A. F. González-Córdova, M. J. Torres-Llanez, H. S. Garcia and B. Vallejo-Cordoba, Novel angiotensin I-converting enzyme inhibitory peptides produced in fermented milk by specific wild *Lactococcus lactis* strains, *J. Dairy Sci.*, 2012, **95**(10), 5536–5543.
- 55 Y. Liu and M. Pischetsrieder, Identification and relative quantification of bioactive peptides sequentially released during simulated gastrointestinal digestion of commercial kefir, *J. Agric. Food Chem.*, 2017, **65**(9), 1865–1873.
- 56 M. de Lima, R. A. da Silva, M. F. da Silva, *et al.*, Brazilian kefir-fermented sheep's milk, a source of antimicrobial and antioxidant peptides, *Probiotics Antimicrob. Proteins*, 2018, **10**, 446–455.
- 57 B. Ismail and S. S. Nielsen, Invited review: Plasmin protease in milk: Current knowledge and relevance to dairy industry, *J. Dairy Sci.*, 2010, **93**, 4999–5009.
- 58 J. Law and A. Haandrikman, Proteolytic enzymes of lactic acid bacteria, *Int. Dairy J.*, 1997, **7**(1), 1–11.
- 59 P. S. Tan, B. Poolman and W. N. Konings, Proteolytic enzymes of *Lactococcus lactis*, *J. Dairy Res.*, 1993, **60**(2), 269–286.
- 60 B. Miralles, R. del Barrio, C. Cueva, I. Recio and L. Amigo, Dynamic gastric digestion of a commercial whey protein concentrate, *J. Sci. Food Agric.*, 2018, **98**(5), 1873–1879.
- 61 T. K. Singh, S. K. Øiseth, L. Lundin and L. Day, Influence of heat and shear induced protein aggregation on the in vitro digestion rate of whey proteins, *Food Funct.*, 2014, **5**(11), 2686–2698.
- 62 F. Guyomarc'h, Formation of heat-induced protein aggregates in milk as a means to recover the whey protein fraction in cheese manufacture, and potential of heat-treating milk at alkaline pH values in order to keep its rennet coagulation properties, A review, *Laitiere*, 2006, **86**(1), 1–20.
- 63 T. Baars, C. Berge, J. Garssen and J. Verster, The impact of raw fermented milk products on perceived health and mood among Dutch adults, *Nutr. Food Sci.*, 2019, **49**(6), 1195–1206.
- 64 E. Mendes, M. B. Casaro, C. Fukumori, W. R. Ribeiro, A. L. dos Santos, P. Sartorelli, *et al.*, Preventive oral kefir supplementation protects mice from ovariectomy-induced exacerbated allergic airway inflammation, *Benefic. Microbes*, 2021, **12**(2), 187–197.
- 65 E. Velez, I. Novotny-Nuñez, S. Correa, G. Perdigón and C. Maldonado-Galdeano, Modulation of gut immune response by probiotic fermented milk consumption to control IgE in a respiratory allergy model, *Benefic. Microbes*, 2021, **12**(2), 175–186.
- 66 L. Zhao, F. Shi, Q. Xie, Y. Zhang, S. E. Evvie, X. Li, *et al.*, Co-fermented cow milk protein by *Lactobacillus helveticus* KLDS 1.8701 and *Lactobacillus plantarum* KLDS 1.0386 attenuates its allergic immune response in Balb/c mice, *J. Dairy Sci.*, 2022, **105**(9), 7190–7202.
- 67 X. Pi, Y. Yang, Y. Sun, Q. Cui, Y. Wan, G. Fu, *et al.*, Recent advances in alleviating food allergenicity through fermentation, *Crit. Rev. Food Sci. Nutr.*, 2022, **62**(26), 7255–7268.
- 68 W. S. Hong, Y. P. Chen and M. J. Chen, The anti-allergic effect of kefir *Lactobacilli*, *J. Food Sci.*, 2010, **75**(8), H244–H253.
- 69 B. Alashkar Alhamwe, L. A. P. M. Meulenbroek, D. H. Veening-Griffioen, T. M. D. Wehkamp, F. Alhamdan, S. Miethe, *et al.*, Decreased histone acetylation levels at Th1 and regulatory loci after induction of food allergy, *Nutrients*, 2020, **12**(10), 3193.
- 70 N. Acevedo, B. Alashkar Alhamwe, L. Caraballo, M. Ding, A. Ferrante, H. Garn, *et al.*, Perinatal and early-life nutrition, epigenetics, and allergy, *Nutrients*, 2021, **13**(3), 724.
- 71 Q. S. Li, Y. Q. Wang, Y. R. Liang and J. L. Lu, The anti-allergic potential of tea: a review of its components, mechanisms and risks, *Food Funct.*, 2021, **12**(1), 57–69.

